This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Giamarellos-Bourboulis, E. J.
Right arrow Articles by Giamarellou, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giamarellos-Bourboulis, E. J.
Right arrow Articles by Giamarellou, H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2003, p. 2445-2449, Vol. 47, No. 8
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.8.2445-2449.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Effective Immunomodulatory Treatment of Escherichia coli Experimental Sepsis with Thalidomide

Evangelos J. Giamarellos-Bourboulis,1 Helen Poulaki,2 Nikolaos Kostomitsopoulos,2 Ismene Dontas,2 Despina Perrea,2 Panayotis E. Karayannacos,2 and Helen Giamarellou1*

4th Department of Internal Medicine,1 Laboratory for Experimental Surgery and Surgical Research, University of Athens Medical School, Athens, Greece2

Received 21 November 2002/ Returned for modification 21 January 2003/ Accepted 9 May 2003

Thalidomide, an agent which inhibits biosynthesis of tumor necrosis factor alpha (TNF-{alpha}) and which is used to treat a variety of chronic inflammatory conditions, was investigated as therapy for experimental sepsis. Sepsis was induced by intraperitoneal injection of 107 CFU of Escherichia coli per kg of body weight to 80 Wistar rats divided into four groups. Group A consisted of 24 control animals that did not receive any pretreatment, group B consisted of 18 vehicle-treated control animals pretreated with seed oil, group C consisted of 30 rats administered thalidomide diluted in seed oil at a dose of 50 mg/kg 30 min before bacterial challenge, and group D consisted of eight animals that were not challenged with E. coli but that were used for white blood cell count determination. Sepsis was determined by measurement of vital signs before and 6 h after bacterial challenge. After 6 h the animals were killed and blood was sampled for culture; white blood cell count determination; and determination of endotoxin (lipopolysaccharide), TNF-{alpha}, interleukin-1ß (IL-1ß), and IL-6 levels. The levels of these cytokines were also estimated in the supernatants of human monocytes pretreated with thalidomide after exposure to the isolate. Sepsis developed in all vehicle-treated control animals and controls by 6 h after bacterial challenge but in only 10 animals (33.3%) pretreated with thalidomide (P < 0.0001). Six hours after bacterial challenge all animals had similar levels of endotoxemia, IL-1ß, and IL-6. The mean white blood cell count for groups A, B, and C were 5,631.1, 2,638.9, and 8,169.3 cells/µl, respectively (P value between groups, <0.0001); the TNF-{alpha} levels were 77.3, 107.2, and 26.1 pg/ml, respectively (P values between groups, <0.0001). Pretreatment of human monocytes with thalidomide prevented the secretion of TNF-{alpha} and IL-1ß but not that of IL-6. It is concluded that thalidomide exerts a considerable anti-inflammatory effect by preventing evolution to sepsis and by decreasing the level of production of TNF-{alpha} and therefore deserves to be further evaluated in research for the therapy of sepsis.

* Corresponding author. Mailing address: 4th Department of Internal Medicine, Sismanoglion General Hospital, 151 26 Maroussi Attikis, Greece. Phone: (30210) 80 39 542. Fax: (30210) 80 39 543. E-mail: giamarel{at}internet.gr.

Antimicrobial Agents and Chemotherapy, August 2003, p. 2445-2449, Vol. 47, No. 8
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.8.2445-2449.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Giamarellos-Bourboulis, E. J., Adamis, T., Laoutaris, G., Sabracos, L., Koussoulas, V., Mouktaroudi, M., Perrea, D., Karayannacos, P. E., Giamarellou, H. (2004). Immunomodulatory Clarithromycin Treatment of Experimental Sepsis and Acute Pyelonephritis Caused by Multidrug-Resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 48: 93-99 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»